FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically to a method of treating chronic obstructive pulmonary disease (COPD) in humans. That is ensured by administering 100 mg of benralizumab to a patient with at least one four-week dosing interval and then with at least one eight-week dosing interval. In the above treatment, the rate of exacerbations of COPD is reduced in the patients having at least 200 eosinophils/mcl. Volume of forced exhalation is also increased in the patient with COPD.
EFFECT: group of inventions provides the alleviation of the patients with the reduced manifestations of COPD symptoms.
16 cl, 12 dwg, 15 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR INCREASING FORCED EXPIRATORY VOLUME IN ASTHMATIC PATIENTS USING BENRALIZUMAB | 2014 |
|
RU2703568C2 |
| METHODS FOR REDUCING EXACERBATION RATES OF ASTHMA USING OF BENRALIZUMAB | 2014 |
|
RU2676333C2 |
| METHODS FOR NORMALIZING ASTHMA SYMPTOMS USING BENRALIZUMAB | 2014 |
|
RU2728578C2 |
| METHODS OF NORMALIZING ASTHMA SYMPTOMS USING BENRALIZUMAB | 2020 |
|
RU2840902C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST | 2020 |
|
RU2838119C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2020 |
|
RU2832774C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST | 2018 |
|
RU2793745C2 |
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| DIAGNOSTICS AND TREATMENT METHODS ASSOCIATED WITH TH2 INHIBITION | 2011 |
|
RU2737245C2 |
